Jerzy Leszczynski to Drug Design
This is a "connection" page, showing publications Jerzy Leszczynski has written about Drug Design.
Connection Strength
2.583
-
Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov. 2020 12; 15(12):1473-1487.
Score: 0.700
-
Samanta PN, Kar S, Leszczynski J. Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors. Curr Pharm Des. 2019; 25(7):750-773.
Score: 0.627
-
Ahmed L, Rasulev B, Kar S, Krupa P, Mozolewska MA, Leszczynski J. Inhibitors or toxins? Large library target-specific screening of fullerene-based nanoparticles for drug design purpose. Nanoscale. 2017 Jul 27; 9(29):10263-10276.
Score: 0.568
-
Sokalski WA, Burda JV, Leszczynski J. International conference: Modeling and Design of Molecular Materials--MDMM 2010 (4-8 July 2010, Wroclaw, Poland). J Mol Model. 2011 Sep; 17(9):2131.
Score: 0.377
-
Kar S, Roy K, Leszczynski J. In Silico Tools and Software to Predict ADMET of New Drug Candidates. Methods Mol Biol. 2022; 2425:85-115.
Score: 0.193
-
Toropov AA, Toropova AP, Benfenati E, Gini G, Leszczynska D, Leszczynski J. Calculation of molecular features with apparent impact on both activity of mutagens and activity of anticancer agents. Anticancer Agents Med Chem. 2012 Sep; 12(7):807-17.
Score: 0.101
-
Sponer JE, Leszczynski J, Sponer J. Mechanism of action of anticancer titanocene derivatives: an insight from quantum chemical calculations. J Phys Chem B. 2006 Oct 05; 110(39):19632-6.
Score: 0.017